Novo Nordisk board members disclose share vesting transactions
Novo Nordisk issued a regulatory announcement on 6 August 2026 detailing share transactions by its board members, executives and related persons, as required by EU market abuse regulation.
The filing lists two individuals - board member Désirée Jantzen Asgreen and executive Elisabeth Dahl Christensen - who each reported vesting of restricted shares under the company’s 100th Anniversary Shares programme. The transactions involved 74 shares at a price of DKK 294.30 per share, totaling about DKK 21,778.
The transactions were recorded on 5 August 2026 and executed outside a trading venue. The company has submitted the information to comply with Article 19 of Regulation No. 596/2014.
This writeup was produced by pharmadog from original reporting by globenewswire health.
Original headline: “Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons”
read at globenewswire health ↗
comments(0)
5-min edit window · permanent after that